Blood Pressure Monitor CDSCO Registration — Import License (MD-15) Process

Blood pressure monitors are among the most widely used medical devices in India — deployed across every level of the healthcare system, from primary health centres and general physician clinics to hospital wards, ICUs, and increasingly, patients’ own homes. With India’s growing burden of hypertension, expanding home healthcare adoption, and rising consumer awareness of self-monitoring, the demand for both clinical-grade and home-use blood pressure monitors continues to grow steadily.

For any overseas manufacturer, Indian importer, or authorised distributor seeking to bring blood pressure monitors into the Indian market, the CDSCO Import Licence (Form MD-15) is the essential regulatory requirement. Without a valid MD-15 licence, no blood pressure monitor — whether for clinical, home, or pharmacy use — can be legally imported, stocked, distributed, or sold in India.

This guide provides a complete, detailed walkthrough of the MD-15 import licence process for blood pressure monitors — covering device classification, the complete documentation checklist, applicable standards, and the practical steps to achieving CDSCO approval efficiently.

What is the CDSCO MD-15 Import Licence for Blood Pressure Monitors?

The MD-15 Import Licence is the formal Market Authorisation issued by the Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare, Government of India, permitting an Indian entity to commercially import a specific blood pressure monitor model from a specific overseas manufacturer for sale in India.

The process flows as follows:

• Form MD-14 — the application form for import licence, filed through the CDSCO SUGAM online portal 
• Form MD-15 — the import licence issued by CDSCO upon successful review and approval

Key Characteristics of the MD-15 Licence

Device-specific: Covers only the specific blood pressure monitor models and variants listed in the application.

Manufacturer-specific: Tied to a single overseas manufacturing facility — a different manufacturer requires a separate application.

Importer-specific: Issued in the name of the Indian Authorised Agent (IAA) or importer.

Valid for 5 years: From the date of issue, with renewal required before expiry.

Criminal liability for non-compliance: Importing or selling a blood pressure monitor without a valid MD-15 licence is an offence under the Drugs and Cosmetics Act, 1940 — attracting product seizure, financial penalties, and imprisonment of up to 3 years.

What is a Blood Pressure Monitor — Device Scope

A blood pressure monitor (also called a sphygmomanometer in its traditional manual form) is a medical device used to measure arterial blood pressure — recording systolic and diastolic pressure values, and in most modern devices, pulse rate as well.

Blood Pressure Monitor Types Covered Under MD-15 Registration

Manual / Mercury Sphygmomanometers Traditional manual blood pressure measurement devices using a mercury column or aneroid gauge, an inflatable cuff, and a stethoscope (auscultatory method). Note: mercury-based devices face increasing environmental restrictions globally and in India; aneroid (dial-based) manual sphygmomanometers remain in clinical use.

Aneroid Sphygmomanometers Manual blood pressure devices using a calibrated dial gauge instead of mercury — widely used in clinical settings, requiring periodic calibration verification.

Automated/Digital Upper Arm Blood Pressure Monitors The most common modern format — using oscillometric technology to automatically measure blood pressure via an upper-arm cuff, with digital display of systolic, diastolic, and pulse rate values. Used in clinics, hospitals, and extensively for home use.

Automated/Digital Wrist Blood Pressure Monitors Compact, wrist-worn automated devices using oscillometric technology — popular for home and portable use, though generally considered less accurate than upper-arm devices and subject to specific positioning requirements for valid readings.

Ambulatory Blood Pressure Monitoring (ABPM) Systems Wearable devices that automatically measure and record blood pressure at intervals over a 24-hour (or longer) period during normal daily activity — used for diagnosing white-coat hypertension, masked hypertension, and assessing blood pressure patterns and variability.

Clinical/Hospital-Grade NIBP Modules Non-invasive blood pressure (NIBP) measurement modules integrated within multi-parameter patient monitors — covered separately under patient monitor registration where part of a complete monitor, but standalone NIBP modules may require independent registration.

Connected / App-Integrated Blood Pressure Monitors Blood pressure monitors with Bluetooth or Wi-Fi connectivity, transmitting readings to companion mobile apps for tracking, trend analysis, and sharing with healthcare providers — an increasingly significant category in the consumer and remote patient monitoring space.

Blood Pressure Monitor Cuffs and Accessories Replacement cuffs (adult, paediatric, large adult, thigh sizes) and other accessories sold independently may have specific regulatory considerations as accessories to the primary device.

Regulatory Classification of Blood Pressure Monitors Under MDR 2017

Important: Classification must be formally determined based on the device’s intended use, measurement technology, and any integrated features — not assumed from the general category. Our regulatory team conducts a formal, device-specific classification analysis before every application.

Who Files the MD-14 Import Licence Application?

The MD-14 application must be filed by the Indian Authorised Agent (IAA) — an entity legally registered in India that acts as the regulatory representative of the overseas blood pressure monitor manufacturer in India.

The IAA must be formally appointed by the foreign manufacturer through a notarised and apostilled Authorisation Letter and a formal IAA Agreement. The IAA:

• Files the MD-14 application on the SUGAM portal
• Bears regulatory responsibility for the device in India — including vigilance reporting, label compliance, and post-market obligations
• Is named on the device label and on the CDSCO registration
• Must be a legally registered Indian business entity

Prerequisites Before Filing the MD-14 Application

Import Export Code (IEC) Issued by the Directorate General of Foreign Trade (DGFT) at dgft.gov.in. Mandatory for all import applications. Government fee: ₹500. Timeline: 2 to 5 working days.

GST Registration Valid GSTIN of the Indian IAA / importer entity.

Business Registration The IAA must be a legally registered Indian business — Certificate of Incorporation (Pvt Ltd / LLP), Partnership Deed, or equivalent.

SUGAM Portal Account The IAA must be registered on the CDSCO SUGAM portal with a valid Digital Signature Certificate (DSC) for application submission.

Complete Documentation Checklist for Blood Pressure Monitor MD-15 Import Licence

SECTION A — Indian Applicant (IAA) Documents

Document 1 — Application in Form MD-14 Accurately completed application form on the CDSCO SUGAM portal with correct details of the IAA, the foreign manufacturer, and all blood pressure monitor models to be imported.

Document 2 — Business Registration Certificate Certificate of Incorporation (for Pvt Ltd / LLP / Public Ltd), Partnership Deed, or LLP Agreement proving the IAA’s legal existence in India.

Document 3 — Import Export Code (IEC) Current IEC certificate issued by DGFT, in the name of the Indian applicant entity.

Document 4 — GST Registration Certificate Valid GSTIN certificate of the Indian IAA / importer.

Document 5 — Authorisation Letter from Foreign Manufacturer A formally executed letter from the overseas manufacturer — notarised and apostilled by the Indian Embassy / Consulate:

• Appointing the Indian entity as their Authorised Agent for India
• Explicitly listing all blood pressure monitor model numbers and cuff size variants covered
• Confirming the scope of appointment (India territory)
• Signed by a duly authorised officer of the foreign entity

Document 6 — Indian Authorised Agent (IAA) Agreement Formal agreement between the foreign manufacturer and the Indian IAA defining regulatory responsibilities, vigilance reporting obligations, and post-market surveillance responsibilities in India.

Document 7 — Affidavit / Undertaking by Indian Applicant Sworn affidavit on non-judicial stamp paper executed by the proprietor / all directors of the IAA entity, declaring full compliance with MDR 2017 and accuracy of all submitted information.

Document 8 — Power of Attorney (if filing through regulatory consultant) Duly executed and notarised Power of Attorney authorising the regulatory consultant to file and manage the application on behalf of the IAA.

SECTION B — Device Technical Documents

Document 9 — Device Description and Intended Use A comprehensive written document covering:

• Full device name, model number(s), and product variants (cuff sizes, connectivity options) included in the application
• Measurement technology — oscillometric, auscultatory (manual), or hybrid
• Intended clinical use — routine blood pressure measurement, ambulatory monitoring, screening
• Intended clinical environment — clinic, hospital ward, pharmacy, home use
• Intended users — physicians, nurses, trained healthcare workers, or patients/caregivers (for home-use devices)
• Intended patient population — adult, paediatric (note: paediatric BP measurement requires specific cuff sizing and validation considerations)
• Contraindications and limitations — e.g., not validated for use during arrhythmia, pregnancy-related hypertension (pre-eclampsia) unless specifically validated for this population
• Description of all components — main unit, cuff(s), tubing, bladder, display, connectivity module (where applicable)
• Description of any companion mobile app or data connectivity features

Document 10 — Technical Specifications Detailed performance specifications including:

• Measurement method (oscillometric / auscultatory)
• Measurement range — systolic pressure range, diastolic pressure range, pulse rate range
• Measurement accuracy — typically specified as ±3 mmHg for pressure and ±5% for pulse rate (per applicable validation standards)
• Cuff pressure range and inflation/deflation specifications
• Cuff size range(s) and corresponding arm/wrist circumference specifications
• Display specifications
• Memory/data storage capacity (for devices with reading storage)
• Connectivity specifications — Bluetooth, Wi-Fi, USB (where applicable)
• Battery type and life / power supply specifications
• Irregular heartbeat detection feature specifications (where present)
• Hypertension indicator / WHO blood pressure classification display feature (where present)
• Dimensions and weight
• Operating environmental conditions (temperature, humidity range)

Document 11 — Essential Principles Checklist (Schedule III — MDR 2017) A comprehensive document demonstrating how the blood pressure monitor satisfies each applicable Essential Principle of Safety and Performance under Schedule III of the Medical Devices Rules, 2017 — with specific references to the standards, test reports, and clinical data used to demonstrate conformity with each principle.

Document 12 — Risk Management File (ISO 14971:2019) Complete risk management documentation prepared in accordance with ISO 14971:2019, covering:

Hazard Identification specific to blood pressure monitors:

• Inaccurate measurement leading to misdiagnosis or inappropriate treatment decisions
• Incorrect cuff size selection leading to measurement error
• Excessive cuff inflation pressure causing patient discomfort or injury (particularly relevant for elderly or fragile-skin patients)
• Cuff malfunction (air leak, bladder failure)
• Measurement failure in patients with arrhythmia (a known limitation of oscillometric technology)
• Battery/power failure during measurement
• Data transmission/connectivity errors (for connected devices)
• Misinterpretation of displayed results by lay users (for home-use devices)

Risk Estimation, Evaluation, and Control:

• Risk control measures and their effectiveness verification
• Residual risk assessment
• Benefit-risk analysis conclusion

Document 13 — Software Documentation (IEC 62304) — for digital/connected devices For automated digital blood pressure monitors with embedded software and any connected/app-integrated devices:

• Software description — measurement algorithm, display management, data storage, connectivity functions
• Software safety classification per IEC 62304
• Software verification and validation records
• Cybersecurity assessment (IEC 81001-5-1) for Bluetooth/Wi-Fi connected devices and companion mobile apps

Document 14 — Usability Engineering File (IEC 62366-1) Particularly critical for blood pressure monitors, given the high prevalence of home use by non-clinical, often elderly, users:

• Intended use environment analysis — clinic, home, pharmacy
• User population analysis — clinical professionals vs. lay users (including elderly users, a key demographic for home BP monitoring)
• Use-related hazard identification — incorrect cuff positioning, incorrect cuff size selection, improper posture during measurement, misreading or misinterpreting displayed values
• Formative and summative usability evaluations — particularly important for home-use devices, where summative (human factors) validation with representative lay users is expected
• Residual use-related risk assessment

Document 15 — Biocompatibility Documentation (ISO 10993 Series) For the cuff material and any other components in direct skin contact:

• Biocompatibility assessment addressing relevant endpoints (cytotoxicity, sensitisation, irritation) based on the nature (skin contact) and duration of patient contact

SECTION C — Test Reports (Standards Compliance)

All test reports must be issued by NABL-accredited laboratories or laboratories accredited by internationally recognised accreditation bodies (ILAC MRA members).

Document 16 — IEC 60601-1 — General Safety and Essential Performance The foundational standard for all electrically powered medical devices — covering electrical safety, mechanical safety, and essential performance requirements applicable to automated digital blood pressure monitors.

Document 17 — IEC 60601-1-2 — Electromagnetic Compatibility (EMC) Ensures the device operates correctly in environments with common EMC sources and does not emit interference affecting other equipment — relevant for both clinical and home environments.

Document 18 — IEC 60601-1-11 — Home Healthcare Environment Critical standard for home-use blood pressure monitors — specifying additional requirements for medical electrical equipment used in the home healthcare environment, covering the electromagnetic, mechanical, and operational conditions unique to home use (variable power supply quality, handling by untrained users, varied environmental conditions). Mandatory for all blood pressure monitors marketed for home use.

Document 19 — IEC 80601-2-30 — Particular Requirements for the Basic Safety and Essential Performance of Automated Non-Invasive Sphygmomanometers This is the primary product-specific standard for automated digital blood pressure monitors — specifying:

• Measurement accuracy requirements and validation methodology
• Maximum cuff inflation pressure limits and overpressure protection requirements
• Cycle time and measurement duration specifications
• Display accuracy and resolution requirements
• Safety requirements specific to cuff-based pressure application

Document 20 — ISO 81060-2 — Clinical Validation of Automated Sphygmomanometers A critical clinical validation standard specifically for automated (oscillometric) blood pressure monitors — requiring a clinical accuracy validation study comparing the device’s measurements against a validated reference standard (typically auscultatory measurement by trained observers) in a defined sample of human subjects, following a structured protocol. This clinical validation is one of the most scrutinised elements of the CDSCO dossier for automated blood pressure monitors, as measurement accuracy is the core performance claim of the device.

Document 21 — ISO 81060-1 — Non-Automated Sphygmomanometers (for manual devices) Applicable for manual aneroid sphygmomanometers — specifying requirements for these traditional measurement devices.

Document 22 — IEC 62304 — Medical Device Software For digital/automated devices with embedded measurement and display software.

Document 23 — IEC 62366-1 — Usability Engineering Test report or evaluation evidence demonstrating usability validation, particularly the summative (human factors) evaluation for home-use devices.

Document 24 — ISO 10993 Series — Biocompatibility For cuff materials and other skin-contacting components.

SECTION D — Quality Management System Documents

Document 25 — ISO 13485:2016 Certificate Valid QMS certificate from an accredited certification body. The certificate must:

• Be current and within validity at the time of application
• Explicitly include blood pressure monitors / sphygmomanometers in the product scope
• Cover the manufacturing facility (site) where the devices are produced

Document 26 — Quality Management System Overview A brief summary of the manufacturer’s QMS — quality policy, organisational structure, and key processes ensuring continued compliance.

Document 27 — Post-Market Surveillance (PMS) Plan Documented plan for systematic collection, analysis, and action on post-market data — specifying data sources, review frequency, and thresholds for corrective action.

Document 28 — Vigilance Procedures Documented procedures for detecting, evaluating, and reporting serious incidents to CDSCO within prescribed timeframes, and managing Field Safety Corrective Actions.

Document 29 — Periodic Safety Update Report (PSUR) — if available For devices already marketed in other countries, demonstrating an established real-world safety profile.

SECTION E — Clinical Evaluation Documents

Document 30 — Clinical Evaluation Report (CER) A systematic, documented evaluation of clinical data demonstrating that the blood pressure monitor achieves its intended clinical performance and is safe for the intended patient population. For blood pressure monitors, the CER must:

• Reference the device’s ISO 81060-2 clinical validation study results as the primary clinical evidence
• Include a systematic review of relevant published literature on oscillometric blood pressure measurement accuracy and clinical utility
• Address performance in special populations where claimed (paediatric, pregnancy-related hypertension, arrhythmia patients) with appropriate validation evidence for each claimed population
• Conclude on the adequacy of clinical evidence supporting the intended use claims

Document 31 — Post-Market Clinical Follow-Up (PMCF) Plan A documented plan for continued collection of clinical data after market entry in India.

SECTION F — Labelling and Instructions for Use

Document 32 — Device Label (Schedule V — MDR 2017) Proposed label for the blood pressure monitor and its packaging, including:

• Device name and model number
• Manufacturer’s name, address, and contact details
• Country of manufacture
• Indian Authorised Agent’s name, address, and contact details
• Unique Device Identification (UDI)
• Manufacturing date
• Applicable symbols (ISO 15223, IEC 60601)
• Cuff size range and corresponding arm circumference markings
• Power supply specifications
• Applicable warnings

Document 33 — Instructions for Use (IFU) / User Manual Comprehensive user documentation — particularly important for home-use blood pressure monitors where the primary user is the patient:

• Intended use and clinical indications
• Contraindications and precautions (including specific guidance for irregular heartbeat/arrhythmia patients where the device has limitations)
• Cuff size selection guide with measurement instructions
• Correct cuff placement and positioning instructions (with diagrams)
• Measurement procedure — posture, rest period before measurement, multiple reading guidance
• Display interpretation guide — understanding systolic/diastolic/pulse values, hypertension indicator (where present)
• Guidance on when to seek medical advice based on readings
• Battery replacement and power management
• Connectivity setup (for app-connected devices)
• Cleaning and maintenance instructions
• Calibration verification recommendations and schedule
• Troubleshooting guide
• Technical specifications (complete)

SECTION G — Documents from Foreign Manufacturer

Document 34 — Free Sale Certificate (FSC) / Market Authorisation Issued by the competent regulatory authority in the manufacturer’s home country:

• USA: FDA 510(k) clearance for blood pressure monitors
• European Union: CE Certificate under EU MDR 2017/745 or MDD 93/42/EEC from an EU Notified Body
• Australia: TGA ARTG registration
• Canada: Health Canada Medical Device Licence
• Japan: PMDA approval

Must be apostilled or legalised by the Indian Embassy / Consulate in the manufacturer’s country.

Document 35 — Manufacturing Licence of Foreign Facility Proof that the manufacturing site holds valid manufacturing licence or equivalent regulatory authorisation.

Document 36 — GMP Compliance Certificate / ISO 13485 Certificate Evidence of Good Manufacturing Practices compliance at the manufacturing facility.

Document 37 — Site Master File (SMF) A structured document describing the manufacturing site, organisational structure, products manufactured, processes, and QMS overview.

Document 38 — Declaration of Conformity A formal, signed declaration by the foreign manufacturer that the blood pressure monitor conforms to all applicable requirements of MDR 2017 and Essential Principles of Safety and Performance.

Step-by-Step MD-15 Import Licence Process for Blood Pressure Monitors

Step 1 — Free Regulatory Assessment and Classification

Our team reviews the blood pressure monitor’s measurement technology, intended use (clinical or home), and existing certifications to determine the correct classification and documentation requirements.

Step 2 — IAA Setup and Prerequisites

We verify or establish IEC, GST registration, SUGAM portal account, and IAA Agreement.

Step 3 — Foreign Manufacturer Documentation

We coordinate with the overseas manufacturer to obtain the apostilled Authorisation Letter, FSC, ISO 13485 certificate, Site Master File, and Declaration of Conformity.

Step 4 — Technical Dossier Preparation

We prepare or thoroughly review the Device Description, Essential Principles Checklist, Risk Management File, Software Documentation, Usability Engineering File, and Clinical Evaluation Report.

Step 5 — Test Report and Clinical Validation Gap Analysis

We verify the availability and adequacy of all required test reports — with particular focus on:

• IEC 80601-2-30 (device-specific performance standard)
• ISO 81060-2 (clinical validation study) — confirming the study design and results adequately support the device’s accuracy claims
• IEC 60601-1-11 (home healthcare environment, for home-use devices)

Step 6 — Labelling and IFU Review

We review the proposed Indian market label and IFU for compliance with Schedule V of MDR 2017 — with particular attention to home-use guidance clarity, given the predominantly lay-user audience for many blood pressure monitor models.

Step 7 — Application Filing on SUGAM Portal

We manage the complete SUGAM portal submission — Form MD-14 preparation, document uploads, government fee payment, and submission confirmation.

Step 8 — CDSCO Query Response

We prepare technically precise, well-referenced written responses to all CDSCO queries — resolving issues efficiently.

Step 9 — MD-15 Licence Issuance

Upon successful evaluation, CDSCO issues the Form MD-15 Import Licence digitally through the SUGAM portal. We deliver the licence with a full post-licence compliance briefing.

Step 10 — Post-Licence Compliance Programme

We establish your ongoing compliance framework — vigilance reporting procedures, PSUR preparation schedule (where applicable), label compliance verification, and renewal tracking.

Government Fees

Estimated Timelines

Timelines are estimates and depend on documentation completeness — particularly the availability of a robust ISO 81060-2 clinical validation study — CDSCO workload, and query resolution speed.

Post-MD-15 Compliance Obligations

Label Compliance Every blood pressure monitor imported under the MD-15 licence must bear a label compliant with Schedule V of MDR 2017 on every imported unit.

Vigilance Reporting Serious incidents in India involving the imported blood pressure monitor — significant measurement inaccuracy leading to patient harm, cuff-related injury, device malfunction — must be reported to CDSCO within prescribed timeframes.

Software Update Notifications Updates to measurement algorithms or companion app software affecting safety or performance must be notified to CDSCO before deployment.

Licence Renewal The MD-15 licence expires after 5 years; renewal application must be filed before expiry.

Change Notifications Significant changes — new cuff sizes, new connectivity features, manufacturing site changes — require formal amendment applications to CDSCO.

Common Reasons for MD-14 Application Rejection or Delay

Missing or inadequate ISO 81060-2 clinical validation data The single most common and consequential gap for blood pressure monitor applications — CDSCO requires robust clinical accuracy validation, and bench testing alone is not sufficient.

Non-apostilled or outdated Free Sale Certificate The FSC is not authenticated by the Indian Embassy or does not cover the specific models in the application.

Missing IEC 60601-1-11 compliance for home-use devices Home healthcare environment requirements are sometimes overlooked when the device is marketed for both clinical and home use.

Inadequate usability validation for home-use devices Missing or weak summative usability evaluation data, particularly relevant given the predominantly lay, often elderly, user population for home blood pressure monitors.

Cuff size range not clearly documented and validated Each cuff size variant should have validated accuracy data — a generic claim covering multiple cuff sizes without size-specific validation evidence can trigger CDSCO queries.

Vague claims regarding irregular heartbeat detection or special populations Marketing claims about irregular heartbeat detection, suitability for arrhythmia patients, or pregnancy-related hypertension without specific supporting clinical validation data for these claims.

Frequently Asked Questions 

Q1. Can the same MD-15 licence cover multiple blood pressure monitor models with different cuff sizes? 

Generally, multiple models and cuff size variants from the same manufacturer can be included in a single MD-14 application, provided they share substantially similar technology and validation data, or provided size-specific validation is included for each variant. Significantly different device platforms may require separate applications.

Q2. Is a clinical validation study mandatory for every blood pressure monitor, or can bench testing alone suffice? 

A clinical validation study compliant with ISO 81060-2 is expected for automated (oscillometric) blood pressure monitors, as the standard specifically requires clinical accuracy validation against a reference measurement method in human subjects — bench/technical testing alone does not satisfy this requirement. This is one of the most important pieces of evidence in the entire CDSCO dossier for these devices.

Q3. Do home-use blood pressure monitors require different documentation than clinic/hospital-use devices? 

Yes, in key respects. Home-use devices require IEC 60601-1-11 (home healthcare environment) compliance and more extensive usability engineering validation (given the lay, often elderly, user population), along with clear, lay-accessible Instructions for Use. Devices intended solely for clinical/professional use have different (though still substantial) usability and environmental considerations.

Q4. Is CE marking under EU MDR sufficient to sell blood pressure monitors in India? 

No. CE certification is submitted as the Free Sale Certificate in the CDSCO application but does not replace the requirement for a separate Indian CDSCO import licence.

Q5. Our blood pressure monitor has a companion app for tracking readings over time. Does the app need separate CDSCO registration? 

If the app functions purely as a data display, storage, and trend-tracking tool without performing independent diagnostic or clinical decision-support functions, it is typically covered as an accessory to the registered device. If the app independently analyses data to provide diagnostic conclusions or clinical recommendations, it may require separate evaluation as a Software as a Medical Device (SaMD). We provide regulatory assessments for companion apps as part of device registration planning.

Q6. Can a wrist blood pressure monitor be registered with the same documentation as an upper-arm monitor? 

Wrist monitors use the same general oscillometric measurement principle but require their own device-specific clinical validation under ISO 81060-2, as measurement accuracy and positioning considerations differ from upper-arm devices. A separate or supplementary validation dataset specific to the wrist monitor’s design is typically required.

Q7. What happens if we import blood pressure monitors before the MD-15 licence is issued? 

Importing medical devices before receiving the MD-15 import licence is a criminal offence under the Drugs and Cosmetics Act, 1940, regardless of quantity or intended use. Consequences include shipment seizure at customs, financial penalties, IEC cancellation, and potential criminal prosecution.

Q8. Are ambulatory blood pressure monitoring (ABPM) systems regulated differently from standard home BP monitors? 

ABPM systems, given their extended wear duration, automated periodic measurement over 24+ hours, and clinical diagnostic role (diagnosing white-coat or masked hypertension), may carry additional documentation requirements around extended-wear usability, data logging accuracy, and clinical validation specific to ambulatory measurement protocols. Classification may also differ from standard intermittent-use BP monitors depending on the specific device design and claims.